Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1975 1
1995 1
1999 2
2000 2
2001 1
2002 2
2003 3
2004 3
2005 7
2006 2
2007 1
2008 1
2009 5
2010 8
2011 4
2012 6
2013 5
2014 8
2015 17
2016 12
2017 17
2018 19
2019 15
2020 19
2021 26
2022 26
2023 24
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Results by year

Citations

2 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment.
Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Chen LK, et al. Among authors: lim ws. J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012. Epub 2020 Feb 4. J Am Med Dir Assoc. 2020. PMID: 32033882
Lifestyle interventions, especially exercise and nutritional supplementation, prevail as mainstays of treatment. Further research is needed to investigate potential long-term benefits of lifestyle interventions, nutritional supplements, or pharmacotherapy for sarcopenia in …
Lifestyle interventions, especially exercise and nutritional supplementation, prevail as mainstays of treatment. Further research is needed …
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. FUNDING: Travere Therapeutics....
Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term …
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
In an 8-week, phase 2 trial, sparsentan, a dual endothelin-angiotensin receptor antagonist, reduced proteinuria in patients with FSGS. The efficacy and safety of longer-term treatment with sparsentan for FSGS are unknown. METHODS: In this phase 3 trial, we enrolled patient …
In an 8-week, phase 2 trial, sparsentan, a dual endothelin-angiotensin receptor antagonist, reduced proteinuria in patients with FSGS. The e …
Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery : An International Randomized Controlled Trial.
Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI, Chan MTV, Borges FK, Leslie K, Duceppe E, Martínez-Zapata MJ, Wang CY, Xavier D, Ofori SN, Wang MK, Efremov S, Landoni G, Kleinlugtenbelt YV, Szczeklik W, Schmartz D, Garg AX, Short TG, Wittmann M, Meyhoff CS, Amir M, Torres D, Patel A, Ruetzler K, Parlow JL, Tandon V, Fleischmann E, Polanczyk CA, Lamy A, Jayaram R, Astrakov SV, Wu WKK, Cheong CC, Ayad S, Kirov M, de Nadal M, Likhvantsev VV, Paniagua P, Aguado HJ, Maheshwari K, Whitlock RP, McGillion MH, Vincent J, Copland I, Balasubramanian K, Biccard BM, Srinathan S, Ismoilov S, Pettit S, Stillo D, Kurz A, Belley-Côté EP, Spence J, McIntyre WF, Bangdiwala SI, Guyatt G, Yusuf S, Devereaux PJ; POISE-3 Trial Investigators and Study Groups. Marcucci M, et al. Ann Intern Med. 2023 May;176(5):605-614. doi: 10.7326/M22-3157. Epub 2023 Apr 25. Ann Intern Med. 2023. PMID: 37094336 Clinical Trial.
PATIENTS: 7490 patients having noncardiac surgery who were at risk for vascular complications and were receiving 1 or more long-term antihypertensive medications. INTERVENTION: In the hypotension-avoidance strategy group, the intraoperative mean arterial pressure target wa …
PATIENTS: 7490 patients having noncardiac surgery who were at risk for vascular complications and were receiving 1 or more long-term …
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety.
Blumenstein I, Shanbhag S, Langguth P, Kalra PA, Zoller H, Lim W. Blumenstein I, et al. Among authors: lim w. Expert Opin Drug Saf. 2021 Jul;20(7):757-769. doi: 10.1080/14740338.2021.1912010. Epub 2021 May 15. Expert Opin Drug Saf. 2021. PMID: 33993818 Review.
Ongoing trials in heart failure will provide additional long-term efficacy and safety data....
Ongoing trials in heart failure will provide additional long-term efficacy and safety data....
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
Cheng Y, Gunasegaran B, Singh HD, Dutertre CA, Loh CY, Lim JQ, Crawford JC, Lee HK, Zhang X, Lee B, Becht E, Lim WJ, Yeong J, Chan CY, Chung A, Goh BKP, Chow PKH, Chan JKY, Ginhoux F, Tai D, Chen J, Lim SG, Zhai W, Choo SP, Newell EW. Cheng Y, et al. Among authors: lim wj. Immunity. 2021 Aug 10;54(8):1825-1840.e7. doi: 10.1016/j.immuni.2021.06.013. Epub 2021 Jul 15. Immunity. 2021. PMID: 34270940 Free article.
Patients with tumor-infiltrating HBV-specific CD8(+) Trm cells exhibited longer-term relapse-free survival. Thus, non-terminally exhausted HBV-specific CD8(+) Trm cells show hallmarks of active involvement and effective antitumor response, implying that these cells could b …
Patients with tumor-infiltrating HBV-specific CD8(+) Trm cells exhibited longer-term relapse-free survival. Thus, non-terminally exha …
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial.
Baek SY, Noh WC, Ahn SH, Kim HA, Ryu JM, Kim SI, Lee EG, Im SA, Jung Y, Park MH, Park KH, Kang SH, Jeong J, Park E, Kim SY, Lee MH, Kim LS, Lim W, Kim S, Kim HJ. Baek SY, et al. Among authors: lim w. J Clin Oncol. 2023 Nov 1;41(31):4864-4871. doi: 10.1200/JCO.23.00557. Epub 2023 Aug 22. J Clin Oncol. 2023. PMID: 37607321 Clinical Trial.
PURPOSE: To determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy (ASTRRA) trial. ...
PURPOSE: To determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone- …
Serpiginous choroiditis.
Lim WK, Buggage RR, Nussenblatt RB. Lim WK, et al. Surv Ophthalmol. 2005 May-Jun;50(3):231-44. doi: 10.1016/j.survophthal.2005.02.010. Surv Ophthalmol. 2005. PMID: 15850812 Review.
Due to the insidious and progressive clinical course, an assessment of treatment outcomes needs long term follow-up. Currently, treatment with immunosuppressive and alkylating agents have shown possible efficacy in small case series. ...
Due to the insidious and progressive clinical course, an assessment of treatment outcomes needs long term follow-up. Currently, treat …
Activity-dependent synapse to nucleus signaling.
Lim AF, Lim WL, Ch'ng TH. Lim AF, et al. Among authors: lim wl. Neurobiol Learn Mem. 2017 Feb;138:78-84. doi: 10.1016/j.nlm.2016.07.024. Epub 2016 Jul 26. Neurobiol Learn Mem. 2017. PMID: 27473670 Review.
A multi-country analysis of COVID-19 hospitalizations by vaccination status.
Gonçalves BP, Jassat W, Baruch J, Hashmi M, Rojek A, Dasgupta A, Martin-Loeches I, Reyes LF, Piubelli C, Citarella BW, Kartsonaki C, Lefèvre B, López Revilla JW, Lunn M, Harrison EM, Kraemer MUG, Shrapnel S, Horby P, Bisoffi Z, Olliaro PL, Merson L; ISARIC Clinical Characterisation Group. Gonçalves BP, et al. Med. 2023 Nov 10;4(11):797-812.e2. doi: 10.1016/j.medj.2023.08.005. Epub 2023 Sep 21. Med. 2023. PMID: 37738979 Free PMC article.
CONCLUSIONS: These findings will inform allocation of healthcare resources in future surges as well as design of longer-term international studies to characterize changes in clinical profile of hospitalized COVID-19 patients related to vaccination history. ...
CONCLUSIONS: These findings will inform allocation of healthcare resources in future surges as well as design of longer-term internat …
216 results